JP2023507816A5 - - Google Patents

Info

Publication number
JP2023507816A5
JP2023507816A5 JP2022538286A JP2022538286A JP2023507816A5 JP 2023507816 A5 JP2023507816 A5 JP 2023507816A5 JP 2022538286 A JP2022538286 A JP 2022538286A JP 2022538286 A JP2022538286 A JP 2022538286A JP 2023507816 A5 JP2023507816 A5 JP 2023507816A5
Authority
JP
Japan
Prior art keywords
composition according
phenyl
methyl
oxy
amino
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2022538286A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023507816A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2020/065335 external-priority patent/WO2021126995A1/en
Publication of JP2023507816A publication Critical patent/JP2023507816A/ja
Publication of JP2023507816A5 publication Critical patent/JP2023507816A5/ja
Pending legal-status Critical Current

Links

JP2022538286A 2019-12-20 2020-12-16 がんを治療するための方法及び組成物 Pending JP2023507816A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201962951479P 2019-12-20 2019-12-20
US62/951,479 2019-12-20
US202063114930P 2020-11-17 2020-11-17
US63/114,930 2020-11-17
PCT/US2020/065335 WO2021126995A1 (en) 2019-12-20 2020-12-16 Methods and compositions for treating cancer

Publications (2)

Publication Number Publication Date
JP2023507816A JP2023507816A (ja) 2023-02-27
JP2023507816A5 true JP2023507816A5 (https=) 2023-12-26

Family

ID=76478290

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022538286A Pending JP2023507816A (ja) 2019-12-20 2020-12-16 がんを治療するための方法及び組成物

Country Status (4)

Country Link
US (1) US20220356494A1 (https=)
EP (1) EP4077690A4 (https=)
JP (1) JP2023507816A (https=)
WO (1) WO2021126995A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20240398799A1 (en) * 2021-08-19 2024-12-05 Engine Biosciences Pte. Ltd. Compositions and methods for generating synthetic lethality in tumors
WO2023205463A1 (en) 2022-04-22 2023-10-26 Vertex Pharmaceuticals Incorporated Heteroaryl compounds for the treatment of pain
WO2024134516A1 (ko) * 2022-12-23 2024-06-27 주식회사 엘지화학 Ron 억제제로서 신규한 화합물

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008147687A1 (en) * 2007-05-21 2008-12-04 Mayo Foundation For Medical Education And Research Treating pancreatitis
JP6342392B2 (ja) * 2012-07-28 2018-06-13 カリター・サイエンシーズ・エルエルシー 置換型ピラゾロン化合物及び使用方法
US9694084B2 (en) * 2014-12-23 2017-07-04 Dana-Farber Cancer Institute, Inc. Methods to induce targeted protein degradation through bifunctional molecules
KR20190039115A (ko) * 2016-07-05 2019-04-10 더 존스 홉킨스 유니버시티 암을 치료하기 위한 crispr/cas9-기반 조성물 및 방법
US20210139889A1 (en) * 2017-06-19 2021-05-13 Yale University Compositions and Methods for Multiplexed Genome Editing and Screening
WO2019014390A1 (en) * 2017-07-12 2019-01-17 Refuge Biotechnologies, Inc. METHODS AND SYSTEMS FOR CONDITIONAL REGULATION OF GENE EXPRESSION
WO2019197605A2 (en) * 2018-04-12 2019-10-17 Umc Utrecht Holding B.V. Drug combinations for use in the treatment of ras-mutant cancer
CA3139969A1 (en) * 2019-06-20 2020-12-24 Dana-Farber Cancer Institute, Inc. Small molecule inhibitors of src tyrosine kinase

Similar Documents

Publication Publication Date Title
JP2023507816A5 (https=)
AU2019204938B2 (en) Mdm2 inhibitors and combinations thereof
US20200325130A1 (en) Proteolysis Targeting Chimera Compounds and Methods of Preparing and Using Same
JP7082263B2 (ja) 造血器悪性腫瘍の治療のための、ｌｓｄ１阻害剤の組合せ
JP2022542396A5 (https=)
US20050209250A1 (en) Therapeutic combinations of atypical antipsychotics with corticotropin releasing factor antagonists
JP2012520867A5 (https=)
RU2012127760A (ru) Bcl-2-селективные апоптоз-индуцирующие средства для лечения рака и иммунных заболеваний
JP2021503458A5 (https=)
RU2007132262A (ru) Соединения и композиции в качестве ингибиторов протеинкиназ
RU2008143703A (ru) ПРИМЕНЕНИЕ ИНГИБИТОРОВ c-Src В КОМБИНАЦИИ С ПИРИМИДИЛАМИНОБЕНЗАМИДОМ ДЛЯ ЛЕЧЕНИЯ ЛЕЙКОЗА
IL269710B2 (en) 2-oxo-thiazole derivatives as a2a inhibitors and compounds for use in cancer therapy
JP2018512403A5 (https=)
HRP20231036T1 (hr) Upotreba braf inhibitora za liječenje kožnih reakcija
EP3274344A1 (en) Formylated n-heterocyclic derivatives as fgfr4 inhibitors
CA2879704A1 (en) Combination of pi3k inhibitor and c-met inhibitor
JP2017525721A (ja) 認知欠損または認知障害に伴って進行する神経障害のおよび神経変性疾患の処置および予防のための製品
US20190375761A1 (en) Inhibitors of RAD52 Recombination Protein and Methods Using Same
JP2025506382A5 (https=)
JP2001516719A5 (https=)
US20160303137A1 (en) Dual pi3k and wnt pathway inhibition as a treatment for cancer
RU2350618C2 (ru) ПРОИЗВОДНЫЕ ХИНАЗОЛИНА В КАЧЕСТВЕ ИНГИБИТОРОВ Src ТИРОЗИНКИНАЗЫ
KR20220059519A (ko) 키나제 억제제에 의한 한선염의 치료
WO2016193955A1 (en) Combinations of kinase inhibitors for treating colorectal cancer
JP2021503457A5 (https=)